SYGGF - Synairgen CEO lays out plans for 2023 and beyond
(NewsDirect)
Synairgen PLC (AIM:SNG, OTC:SYGGF) chiefexecutive Richard Marsden talks to Proactive following the release offull year results for calendar year 2022 - a year he says was"quite challenging at times." Marsden discusses the UK-basedrespiratory company's clinical development plan to take the SNG001drug through Phase 3 trials and registration.
The drug is being developed to helppatients with respiratory viruses such as influenza virus, RSV, andSARS- CoV-2. The plan was formulated after a year of data collectionand consultation with experts. He also highlights the company'srelatively strong cash position, which he says will "allow[Synairgen] to get on with" its planned work schedule.
Contact Details
Proactive UKLtd
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.